Drug Profile
Research programme: Parkinson's disease therapies - BiolineRx
Alternative Names: BL-1022; BL-1023Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator BioLineRx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel
- 12 Mar 2009 Preclinical development for Parkinson's Disease is ongoing
- 26 Aug 2006 Preclinical trials in Parkinson's disease in Israel (unspecified route)